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Abstract
Background The SENIORS trial demonstrated that
nebivolol has beneficial effects in patients with heart fail-
ure. However, the role of beta-blocker therapy in patients
with heart failure and preserved left ventricular ejection
fraction (HFPEF) is still unsettled.
Objective To assess the long-term effects of administra-
tion of nebivolol, compared to placebo, on the clinical
symptoms, exercise capacity and parameters of left ven-
tricular (LV) function in patients with HFPEF.
Methods The Effect of Long-term Administration of
Nebivolol on clinical symptoms, exercise capacity and left
ventricular function in patients with Diastolic Dysfunction
(ELANDD) study is a prospective multicenter European
trial in 120 patients with HFPEF randomised to nebivolol
or placebo. HFPEF is defined as symptoms or signs of heart
failure, a LV ejection fraction [45% and evidence of
diastolic LV dysfunction by Doppler echocardiography.
Procedures include a baseline clinical examination, 6-min
walk test (6MWT), electrocardiography, Doppler echo-
cardiography and Minnesota QoL questionnaire. Nebivolol
or placebo is started at 2.5 mg/day and gradually uptitrated
to 10 mg/day. After initiation of the study, patients are
assessed at 1, 2, 5 and 6 weeks (titration phase) and at
weeks 12 and 26. The primary endpoint is the change from
baseline in the 6MWT distance with nebivolol versus
placebo. Sample size calculations are based on an antici-
pated 15% difference (70 m) in the 6MWT distance
between nebivolol and placebo-treated patients. This study
will allow the collection of data regarding the possible
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clinical benefits and the effects on LV function of nebivolol
administration in patients with HFPEF.
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Background and rationale
The prevalence of heart failure (HF) has reached epidemic
proportions in Western countries. Approximately 40–60%
of patients with HF have a normal or nearly normal left
ventricular (LV) ejection fraction (EF) and the main cause
of their symptoms and clinical course is LV diastolic
dysfunction [1, 2]. These patients may have abnormalities
of other indexes of LV systolic function, despite a pre-
served LVEF. On the other hand, patients with reduced
LVEF generally also have diastolic abnormalities. Thus,
these patients are currently referred to as subjects with HF
and preserved LVEF (HFPEF) [3]. Compared to HF with
reduced LVEF, HFPEF is more prevalent in women, black
people, elderly, obese patients, patients with diabetes and
patients with concomitant hypertension and/or left ven-
tricular hypertrophy [1, 2, 4]. The severity of symptoms
and the number of hospital admissions in patients with
HFPEF versus those with reduced LVEF seem to be similar
[5]. Even mortality rates, initially found to be lower com-
pared to that of patients with reduced LVEF, appear now
comparable in some studies [6–9].
Despite its clinical importance, the treatment of HFPEF
remains unsettled [10, 11]. In fact, all the controlled trials
performed to date, except for the digitalis investigation
group, (DIG) trial [12], the study of the effects of nebivolol
intervention on outcomes and rehospitalisation in seniors
with heart failure, (SENIORS) [8, 13], the candesartan in
heart failure: assessment of reduction in mortality and
morbidity (CHARM-Preserved) [9], the perindopril in
elderly people with chronic heart failure (PEP-CHF) study
[14], and the irbesartan in patients with heart failure and
preserved left ventricular systolic function (I-PRESERVE)
[15], included only patients with reduced LVEF (e.g.\25–
40%). Previous studies have shown only slightly favour-
able [9, 12–14] or neutral [15] effects on outcomes of
treatment. A pre-specified analysis of SENIORS, compar-
ing patients with a LVEF B35% with those with a LVEF
[35%, found a similar effect on outcomes in these two
subgroups of patients [8].
Investigations on HFPEF have been hindered by the
demographic characteristics of the patients (elderly, with
comorbidities, etc.) as well as by difficulties in establishing
a definitive diagnosis. In this context, the recently released
consensus statement on how to diagnose HFPEF is a major
step forward [4]. This statement has allowed a more uni-
form design of large multicenter trials aimed at the
assessment of pharmacological therapy in patients with
HFPEF.
The effect of long-term administration of nebivolol on
the clinical symptoms, exercise capacity and left ventric-
ular function in patients with diastolic dysfunction
(ELANDD) trial was designed before the new consensus
statement was issued and was initially based mainly on the
document of the European Study Group on Diastolic Heart
Failure issued in 1998 [16]. When the new European
statement was issued, we recognised its importance and
adopted most of its Doppler-echocardiographic criteria for
the diagnosis of HFPEF as inclusion criteria for our study
[4]. Thus, the present study is among the first using the new
criteria for the diagnosis of HFPEF for patient selection.
Nebivolol is a beta-blocker characterised by a high
degree of selectivity for the beta-1 adrenergic receptors
(ARs), compared to beta-2 ARs, with associated vasodi-
latory properties mediated by nitric oxide release [17] and
probably by beta-3 ARs stimulation of endothelial cells
[18]. Nitric oxide release at the level of the myocardium
has favourable lusitropic effects with a downward shift of
the LV pressure–volume relation in the diastolic phase and
lower LV filling pressures [19]. We therefore hypothesised
that nebivolol may improve cardiac function in patients
with HFPEF through its NO-releasing activity. Previously,
we already showed beneficial effects of nebivolol, com-
pared to atenolol, on LV filling pressure and exercise tol-
erance in a single centre comparison trial [20]. Based on
experimental and in vitro analyses and small trials in
patients, the hypothesis tested in ELANDD was that
nebivolol, compared to placebo, might beneficially affect
symptoms and cardiac function in patients with HFPEF.
Study design and patients’ selection
ELANDD is a multicenter, double-blind, placebo-
controlled, randomised, parallel group trial involving 12
European centers. The trial is funded by a grant from
Menarini.
Inclusion criteria
Original inclusion criteria were the following:
• Written informed consent to the study.
• Age C 40 years.
• Documented history of HF with persistent symptoms
during effort (NYHA class II–III).
• LVEF C 45% and LV end-diastolic internal diameter
\3.2 cm/m2 or LV end-diastolic volume index \102
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ml/m2 by echocardiography or radionuclide ventricu-
lography or nuclear magnetic imaging.
• Any abnormality of LV diastolic function docu-
mented by echocardiography, according to the guide-
lines of the European Study Group on Diastolic
Heart Failure [16]. This inclusion criterion was
revised in April 2007 following the online publica-
tion of the new European guidelines for the diagnosis
of HFPEF [4]. The detection of any abnormality in
LV diastolic function was substituted by the detec-
tion of an E/E0 ratio [15 at tissue Doppler echocar-
diography. Patients with a E/E0 ratio between 8 and
15 had to show additional abnormalities of diastolic
function such as an E/A ratio \0.5 and a deceleration
half-time [280 ms (patients older than 50 years) or a
duration of reverse pulmonary vein atrial systole
flow: mitral valve atrial wave flow [30 ms or a left
atrial volume index [40 mL/m2 or increased LV
mass index [4].
Major exclusion criteria
• Patients unable to perform 6-mi walking test
• Planned invasive cardiac procedures or cardiac surgery
during the time of the study
• Recent (\3 months) acute coronary syndrome or
stroke
• Exercise-induced myocardial ischaemia as main cause
of exercise limitation as shown by symptoms (angina)
or by previous exams (exercise test, stress echocardi-
ography or myocardial scintigraphy)
• Concomitant diseases (COPD, peripheral vasculopathy,
orthopaedic disease) as main cause of exercise
limitation
• Major contraindications to beta-blocker therapy (sinus
bradycardia, \50/min; atrio-ventricular block, bron-
chial asthma sensitive to beta-agonists administration)
• Ongoing treatment with beta-blockers, diltiazem or
verapamil
• Systolic blood pressure \100 mm Hg
• Pregnancy, breast feeding or childbearing potential
during the study
• History of alcohol or other illicit drug abuse
• Expected poor compliance to drug therapy
• Participation in any other clinical trial with an inves-
tigational product or scheduled to receive any such
product during the study or in the 4 weeks following
the study
• Suffering from any other medical condition that may
exclude the patient for safety reasons or interfere with
the objective of the study.
Endpoints
The aim of the ELANDD study is to assess the long-term
effects of the administration of nebivolol, compared to
placebo, on the clinical symptoms, exercise capacity and
parameters of left ventricular function in the patients with
HFPEF. The primary endpoint of the study is the change
from baseline in the distance walked during the 6-min
walking test (6MWT) after 6 months of treatment with
nebivolol versus placebo. Additional secondary endpoints
are the changes from baseline after 6 months, with nebiv-
olol versus placebo, in the following measurements:
• Symptoms, assessed using a five-level scale (extremely
worsened, moderately worsened, unchanged, moder-
ately improved, extremely improved);
• New York Heart Association (NYHA) functional class;
• Minnesota living with heart failure questionnaire [21];
• Maximal exercise duration, peak oxygen consumption,
[VO2] and slope of the minute ventilation [VE] to
carbon dioxide [VCO2] relation, at cardiopulmonary
exercise testing.
• Changes in parameters related to LV diastolic function,
including peak E velocity at the Doppler recording of
transmitral inflow tracing, peak E0 velocity of the mitral
valve annulus measured at the level of the septal and
lateral wall, respectively, by tissue Doppler recording,
and the E/E0 ratio.
Lastly, the effects of treatment on major outcomes
(death, hospitalization and unexpected visit to the outpa-
tient clinic or heart failure unit) as well as adverse events
are assessed.
Procedures
Screening, titration and maintenance phases
Written informed consent, history and patients’ baseline
data are collected during the screening phase. Once eligi-
bility has been ascertained, patients undergo baseline
clinical evaluation and procedures (e.g. 6MWT, tissue
Doppler echocardiography, cardiopulmonary exercise test,
laboratory exams) and are then randomised in less than
1 week to either nebivolol (2.5 mg daily) or placebo. Study
drug doses are increased during a 5 weeks titration phase:
nebivolol or placebo doses are increased to 5 mg daily at
1 week after randomization and are then increased to
10 mg daily after 4 additional weeks if the heart rate is
[60 beats/min. If an increase to 10 mg is not tolerated the
dose may be reduced to 5 mg once daily. Once adequate
dosing has been achieved, patients enter the maintenance
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phase. During the maintenance phase, patient visits are at
12 and 26 weeks after initiation of the study. Changes in
dosing or study drug withdrawal are allowed in case of
major changes in the clinical conditions or adverse events
throughout the study.
Study ends at the 26 weeks visit. On the day of this visit,
patients repeat all the procedures performed at baseline in
order to assess the effects of treatment. Baseline and fol-
low-up assessments are shown in Fig. 1.
Echocardiography
Echocardiography is performed at rest, with the patient in
the left lateral position, using commercially available
instruments with a multifrequency phased-array transducer
of 1.5–2.5 MHz. Echocardiographic measurements are
shown in Table 1. Two-dimensional guided M-mode
measurements of the left atrial and LV internal dimensions
and of the end-diastolic septum and posterior wall thick-
ness are made at the LV minor axis at the level of the
chordae tendinae just below the level of the mitral leaflet
tips, as recommended by the American Society of Echo-
cardiography (ASE) [22]. LV mass is calculated using the
Penn convention [23] according to the equation: LV
mass = 1.04 [(LV end-diastolic diameter ? posterior wall
thickness ? interventricular septum thickness)3 - (LV
end-diastolic diameter)3] - 13.6 g, normalized for body
surface area. The transmitral flow velocity is measured
using pulsed-wave Doppler with the sample volume posi-
tioned between the mitral leaflet tips during diastole. Rel-
ative wall thickness (RWT) at end-diastole and end-systole
is calculated as the ratio of the end-diastolic and end-sys-
tolic posterior wall thickness (PWT) to the left ventricular
internal radius (LVIDd) according to the formula:
(2 9 PWTd)/LVIDd. The E-wave and A-wave peak
velocities, the ratio of the E-wave to the A-wave peak
velocities (E/A ratio), E-myocardium (of septal wall), and
pulmonary veins (S, D, AR) velocities are measured on
three separate beats and then averaged. The isovolumic
relaxation time (ms) is measured as the time interval
between the end of left ventricular outflow and the start of
the left ventricular inflow using simultaneous registrations
of outflow and inflow signals by high-pulse repetition
frequency pulsed-wave Doppler. The left atrial diameter,
mitral valve deceleration time (ms), and atrial filling frac-
tion are measured according to standard methods [24]. The
Week 0 Week 1 Week 5 Week 6 Week 12 Week 26 
Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Visit Description 
Visit Window
Screening
Randomization 
Step 2 
(-2/+2 d) 
Step 3 
(-7/+7 d) 
Telephone
consult
(-2/+2 d) 
Follow up 
(-6/+6 d) 
End of study 
(-14/+14 d) 
Informed Consent X
In- and Exclusion criteria X      
  X yhpargomeD     
  X  yrotsiH lacideM     
Concomitant Drug Treatment X X X X X X 
Adverse Events/Serious Adverse 
Events 
 X X X X X 
      X tseT ycnangerP
Adequate contraception X X X  X X 
NYHA functional class X  X   X 
Quality of life (Minnesota) X  X  X X 
Physical Examination X     X 
Blood Pressure X X X  X X 
Heart Rate (*pulse on visit 4) X X X X* X X 
 X     X thgieH/thgieW
Drug Compliance/Accountability X X X  X X 
Blood Sampling for routine analysis X     X 
Sampling NT Pro-BNP X  X   X 
 X X  X X X GCE dael-21
 X     X tset gniklaw setunim 6
VO2  X     X xam 
 X     X  yhpargoidracohcE
X noitazimodnaR     
    X  X X noitartiT
Dispense study medication  X X X  X  
End of Trial    X 
Fig. 1 Summary of baseline
and follow-up measurements.
NYHA New York Heart
Association, NT-
proBNP N-terminal pro
brain natriuretic peptide,
ECG electrocardiogram, VO2
max maximal oxygen uptake
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investigators are encouraged to perform the echocardio-
graphic evaluation as complete as possible. A secondary
analysis of the echocardiographic parameters is done sep-
arately with the data available.
Isovolumic LV relaxation time (IVRT), the ratio of peak
early (E) to peak atrial (A) Doppler mitral valve inflow
velocity, deceleration time (DT) of early Doppler mitral
inflow velocity and ratio of pulmonary vein systolic (S) and
diastolic (D) flow velocities were originally considered to
be indicative of diastolic LV dysfunction if they exceeded
specific cutoff values indexed for age groups [16, 25].
Tissue Doppler-derived indices, namely, LV lengthening
velocities, were later shown to allow a more accurate
assessment of LV diastolic function and filling pressure
[25]. Tissue Doppler imaging (TDI) was performed using
minimal gain to obtain the best signal/noise ratio. In the
apical 4-chamber view, the sample volume was set at
5 9 5 mm and placed 0.5–1 cm over the junction of the
LV septal and lateral wall with the mitral annulus. Peak
velocities during systole (S), early diastole (E0), and late
diastole (A0) were measured. Values represented the aver-
age value of the three cycles and the mean values of the
septal and lateral wall were used. Thus, the ratio between
the early mitral inflow velocity (E) and the early diastolic
(E0) lengthening velocity is nowadays considered as the
most accurate parameter to assess LV diastolic function
[4]. This measurement has therefore been used as a
patient inclusion criterion in 2007, following diffusion of
the new guidelines by the heart failure and echocardiog-
raphy associations of the European Society of Cardiology
(ESC).
Exercise tests
The 6MWT is performed according to standard procedures
[26].
Cardiopulmonary exercise testing is performed in all the
patients who do not have specific limitations and are able to
pedal on a cycle ergometer. Exercise is performed on a
cycle ergometer with the patient in the sitting position with
simultaneous expiratory gas exchange monitoring. Exer-
cise is started at a work load of 0 W, with further incre-
ments of 20 W every 2 min, at a velocity of 50 rpm, up to
the appearance of limiting dyspnea or fatigue. Electrocar-
diographic and respiratory variables are continuously
monitored. Peak VO2 is obtained averaging the final 30 s of
exercise. The anaerobic threshold and the VE/VCO2 slope
are measured by standard criteria [27]. All patients will
have performed at least one preliminary exercise test in
order to be familiar with the procedure and to ensure sta-
bility of the results.
Data collection and endpoint monitoring
All data will be recorded in the case record forms and will
be transferred to the central database at the trial coordi-
nation center, which is regularly backed up and password
protected. The case record forms are monitored at regular
times by the study monitor.
All (possible) endpoints are sent (by fax or mail) to the
trial coordination center as soon as they are detected.
Statistical considerations
The size of the study group has been calculated on the basis
of the predicted change in the 6-min walking distance after
chronic nebivolol administration. According to previous
trials, patients with HFPEF may have a similar impairment
of exercise capacity, compared to those with systolic HF
[23]. In a previous study in patients with LV systolic
dysfunction, we found an increase in the 6MWT from
416 ± 121 to 479 ± 138 m with metoprolol treatment and
from 447 ± 136 to 497 ± 126 m with carvedilol treatment
(n.s. for differences between the two agents; both
p \ 0.001 for changes from baseline) [28]. We assumed
that nebivolol administration may be conservatively asso-
ciated in the patients enrolled in ELANDD with a similar
improvement in 6-min test walk distance from baseline
versus no change from baseline in the placebo group. Thus,
assuming a 10% dropout rate and a 15% difference (70 m)
Table 1 Echocardiographic
measurements of systolic and
diastolic left ventricular
function
LV-ED Left atrial diameter MV inflow, E and A peak VTI
LV-ES Aorta root diameter PV, peak S
IVS-ED Iso-volumetric relaxation time PV, peak D
LVPW-ED MV inflow, peak E PV, peak A
LVOT, HR MV inflow, peak A PV, AR duration
LVOT, R-R interval MV inflow, deceleration time E Peak E0 septal annulus
LVOT, peak MV inflow, A-duration Peak E0 lateral annulus
LVOT, TVI syst MV inflow, diastolic filling period EDV (biplane Simpson)
LVOT, deceleration time MV inflow, VTI E ESV (biplane Simpson)
LVOT diameter MV inflow, VTI A
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in the increase in the 6-min walk distance between the
nebivolol and the placebo treatment groups, we have cal-
culated that a sample size of 118 patients (59 in each
group) would detect a difference of 70 m, at a standard
deviation of 140 m, as statistically significant at a = 0.05
(two tailed) and b = 0.20 (power 80%) in the change of the
6-min walking distance between the two study groups. The
planned study sample size was therefore set at 118 patients.
Discussion and conclusions
Despite the fact that HFPEF accounts for approximately
50% of the admissions for acute HF, its treatment is still
unsettled. Only a few trials have included these patients
and have often yielded less significant results, compared to
trials in patients with reduced LVEF [9, 13, 14]. There are
multiple reasons for these findings, including the older age,
greater prevalence of comorbidities, as well as the inclu-
sion of patients in whom cardiac dysfunction was likely not
the main cause of symptoms [29, 30]. Thus, scrutinized
patient selection has become a must for any assessment of
the effects of treatment in patients with HFPEF. We have
therefore chosen to use the criteria proposed by the ESC [3,
16]. The protocol of the present study has therefore been
amended in 2007 according to the definition of HFPEF in
the new consensus statement [4]. Because of similarities of the
values, the cutoff values for LVEF and LV end-diastolic
volume used in the former European document (LVEF C
45% and LV end-diastolic volume index B 102 ml/m2) [6]
have not been changed to the values stated in the new con-
sensus statement (LVEF [ 50% and LV end-diastolic volume
\97 ml/m2) [4].
Our inclusion criteria were mainly based on Doppler and
tissue Doppler-echocardiographic measurements. Diag-
nostic criteria, used in the new consensus statement but not
in its former edition, such as atrial fibrillation and natri-
uretic peptides plasma levels were still not used for our
trial. It is possible that BNP and NT-ProBNP measure-
ments may be a valid surrogate to these measurements for
screening purposes [3, 4]. However, until the use of these
measurements is prospectively validated, tissue Doppler-
echocardiographic parameters remain the gold standard, at
least for small, mechanistic studies, like ELANDD.
ELANDD is actually one of the first studies in which the
criteria of ESC were actively used for patient inclusion.
Differently from previous mechanistic studies, however,
a clinical endpoint, rather than a Doppler-echocardiogra-
phy measurement, was chosen as primary endpoint of the
study. This was based on multiple considerations. First,
Doppler-echocardiographic measurements had not shown
major changes with beta-blocker therapy in patients with
HFPEF [31]. Second, the 6-min walking test distance is
related to symptoms as well as to patients’ outcomes [26,
28, 32, 33] and it is less dependent on peak exercise heart
rate, a limiting factor for exercise capacity in HFPEF [34].
Third, single center trials have shown that walking distance
is responsive to therapeutic changes, including beta-
blockers [28]. However, until now, these agents have not
been associated with significant benefits in exercise
capacity in patients with heart failure in multicenter trials
[33]. Nebivolol may have many beneficial effects on
exercise performance in patients with HF and, especially,
in those with HFPEF. These include a NO-mediated
downward shift in the LV pressure–volume relationship
[19] with lower LV filling pressure during exercise [20],
peripheral vasodilation with increased skeletal muscle
blood flow [17, 24], selective beta-1 ARs blockade with
reduced heart rate and increased filling time. ELANDD
was therefore designed to test the hypothesis that nebivolol
can be associated with improved symptoms and exercise
tolerance, in patients with HFPEF.
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